Financial Data and Key Metrics Changes - Net revenue for the second quarter was $102.2 million, down 12% year-over-year and down 13% on a constant currency basis [16] - Product revenue decreased by 26% overall and 28% on a constant currency basis, primarily due to lower-than-expected product revenue in China [16] - Service revenue was $57.2 million, up 4% from the prior year and up 3% on a constant currency basis [16] - Overall gross margin for the quarter was 23.5%, down from 36.1% in the prior year, with product gross margins at 19.7% compared to 43.5% in the prior year [18] - Operating loss for the quarter was $11.6 million compared to an income of $4.7 million in the prior year [21] - Adjusted EBITDA for the quarter was a loss of $1.9 million compared to positive $9.6 million in the prior year [21] Business Line Data and Key Metrics Changes - Product gross orders for the second quarter were approximately $66 million, with a book-to-bill ratio of 1.5x [17] - Service gross margins were 26.6%, down from 27.7% in the prior year, primarily due to higher net parts consumption [19] Market Data and Key Metrics Changes - The company ended the second quarter with a reported order backlog of approximately $383 million, representing over 18 months of product revenue [17] - The decline in product revenue was significantly impacted by ongoing geopolitical tensions and tariffs affecting the China market [13][16] Company Strategy and Development Direction - The company announced a comprehensive strategic, operational, and organizational transformation plan aimed at improving accountability, cost control, and execution [6] - The transformation plan targets an approximately $25 million improvement in annualized operating profitability, including a workforce reduction of about 15% [7] - The company is shifting towards a comprehensive solutions-oriented service offering to increase customer uptime and drive higher-margin recurring revenue [8][10] Management's Comments on Operating Environment and Future Outlook - The management acknowledged that external pressures, including tariffs and geopolitical instability, have affected demand patterns and commercial activity [13][14] - The revised revenue guidance for fiscal 2026 is now in the range of $440 million-$450 million, with adjusted EBITDA guidance of $22 million-$25 million [14] - Despite external headwinds, the company remains focused on delivering against transformation commitments and strengthening its foundation for sustained, profitable growth [15] Other Important Information - The company expects approximately $10 million of restructuring charges across the second, third, and fourth fiscal quarters related to workforce reductions and other implementation costs [8] - The leadership team emphasizes the need for teamwork, cross-functional collaboration, and data-driven decision-making to create a performance-driven environment [12] Q&A Session Summary Question: Revenue guidance cut details - The company clarified that the revenue guidance cut was influenced by ongoing tariffs and an unstable geopolitical environment, particularly in China, which has affected demand patterns and commercial activity [26][27][28] Question: Future product gross margins expectations - Product gross margins are expected to be impacted by tariffs and inflation, with projections indicating they may range between 20%-30% depending on product mix and timing of releases [30][32] Question: New initiatives for returning to growth - The company is focusing on solutions-oriented service offerings and restructuring distributor partnerships to drive growth, with expectations for positive results from these initiatives [36][39]

Accuray (NasdaqGS:ARAY) Q2 2026 Earnings call February 04, 2026 04:30 PM ET Company ParticipantsAli Pervaiz - SVP and CFOSteve La Neve - CEOSteve Monroe - VP of Financial Planning and AnalysisConference Call ParticipantsMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystYoung Li - SVP and Equity Research AnalystOperatorGood afternoon and welcome to Accuray's conference call to review financial results for the second quarter of fiscal year 2026, which ended December 31st of 2 ...

Accuray (NasdaqGS:ARAY) Q2 2026 Earnings call February 04, 2026 04:30 PM ET Speaker0Good afternoon and welcome to Accuray's conference call to review financial results for the second quarter of fiscal year 2026, which ended December 31st of 2025. All participants will be in a listen-only mode. Should you need assistance, please signal conference specialists by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press s ...

Accuray (ARAY) 2025 Conference Summary Company Overview - Accuray is a $450 million company operating in the radiation therapy space, with revenue split evenly between product and service offerings [2][3] - Key product lines include Radixact, CyberKnife, Helix, and Tomo C, with the latter two targeting emerging markets and value segments [3][4] Market Position and Strategy - Accuray has doubled its total addressable market through the introduction of Helix and Tomo C, aiming to increase its install base and service contracts [4] - The company holds the number three market share in the radiation oncology industry, with a strong position in Japan where it ranks second [4][5] Tariff Impact and Mitigation Strategies - Recent tariff changes have seen U.S. tariffs on Chinese imports drop from 145% to approximately 30%, while retaliatory tariffs from China have decreased from 125% to 10% [8][10] - Accuray is actively engaging in tariff mitigation strategies, including a duty drawback program and exploring the establishment of a free trade zone in Madison [12][13] - The company is also assessing dual sourcing suppliers to minimize tariff impacts [14][15] Service Revenue and Pricing - Accuray anticipates minimal impact on its service business from current tariff rates, with plans to pass on tariff-related pricing to customers [22][23] - The service segment is viewed as a significant area for margin expansion, with a focus on reducing parts consumption and enhancing service pricing [24] Regional Market Dynamics - The EIMEA region is the largest backlog market for Accuray, with significant growth potential in Japan and emerging markets [26][27] - The company is optimistic about its joint venture in China, which has maintained a high market share in the premium segment [30] Product Performance and Future Markets - The Helix product has performed in line with expectations since its launch, with potential growth anticipated in India and South America [34][35] - Accuray sees India as a key market for future growth, with a significant need for radiation therapy equipment [37][38] U.S. Market Conditions - The U.S. market is currently experiencing pressures due to high interest rates affecting capital equipment decisions [39] - Both the U.S. and Western Europe are primarily replacement markets, with opportunities to upgrade aged systems [42] Service Model Transition - Accuray is in the early stages of transitioning its service offerings towards a subscription model, which is expected to align with customer needs [44] Investor Insights - Key misconceptions about Accuray include its differentiation in technology and the significance of its annuity revenue, which constitutes about half of its total revenue [46] - The company is focused on margin expansion and cost reduction strategies, with hopes that macroeconomic conditions will improve to reflect these efforts in financial performance [47]